Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND Ixekizumab, a high-affinity interleukin-17A (IL-17A) monoclonal antibody, has previously shown efficacy in radiographic axial spondyloarthritis (also known as ankylosing spondylitis). We aimed to evaluate the efficacy and safety of ixekizumab, an IL-17 inhibitor, in non-radiographic axial spondyloarthritis. Here, we report the primary results of COAST-X. METHODS COAST-X was a 52-week, randomised, double-blind, placebo-controlled, parallel-group study done at 107 sites in 15 countries in Europe, Asia, North America, and South America. Eligible participants were adults (aged ≥18 years) with active axial spondyloarthritis without definite radiographic sacroiliitis (non-radiographic axial spondyloarthritis), objective signs of inflammation (via MRI or C-reactive protein), and an inadequate response or intolerance to non-steroidal anti-inflammatory drugs (NSAIDs). Patients were randomly assigned (1:1:1) to receive subcutaneous 80 mg ixekizumab every 4 weeks (Q4W) or every 2 weeks (Q2W), or placebo. Changing background medications or switching to open-label ixekizumab Q2W, or both, was allowed after week 16 at investigator discretion. Primary endpoints were Assessment of SpondyloArthritis international Society-40 (ASAS40) response (defined as an improvement of 40% or more and an absolute improvement from baseline of 2 units or more [range 0-10] in at least three of the four domains [patient global, spinal pain, function, and inflammation] without any worsening in the remaining one domain) at weeks 16 and 52. Patients who switched to open-label ixekizumab were imputed as non-responders in logistic regression analysis. This trial is registered with ClinicalTrials.gov, number NCT02757352. FINDINGS Between Aug 2, 2016, and Jan 29, 2018, 303 patients were enrolled (105 to placebo, 96 to ixekizumab Q4W, and 102 to ixekizumab Q2W). Both primary endpoints were met: ASAS40 at week 16 (ixekizumab Q4W: 34 [35%] of 96, p=0·0094 vs placebo; ixekizumab Q2W: 41 [40%] of 102, p=0·0016; placebo: 20 [19%] of 105) and ASAS40 at week 52 (ixekizumab Q4W: 29 [30%] of 96, p=0·0045; ixekizumab Q2W: 32 [31%] of 102, p=0·0037; placebo: 14 [13%] of 105). 60 (57%) of 104 patients in the placebo group, 63 (66%) of 96 in the ixekizumab Q4W group, and 79 (77%) of 102 in the ixekizumab Q2W group had at least one treatment-emergent adverse event. The most common treatment-emergent adverse events in the ixekizumab groups were nasopharyngitis and injection site reaction. Of the treatment-emergent adverse events of special interest, there was one case of serious infection in the ixekizumab Q4W group. The frequency of serious adverse events was low (four [1%] of 302) and similar across the three groups. There were no malignancies or deaths. No new safety signals were identified. INTERPRETATION Ixekizumab was superior to placebo for improving signs and symptoms in patients with non-radiographic axial spondyloarthritis at weeks 16 and 52. Reports of adverse events were similar to those of previous ixekizumab studies. Ixekizumab offers a potential therapeutic option for patients with non-radiographic axial spondyloarthritis who had an inadequate response or were intolerant to NSAID therapy. FUNDING Eli Lilly and Company.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets
Siddiqui, O., Hung, H. M. J., & O'Neill, R. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400802609797 · Cited by 301
Cited by
Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
Schinocca, C., Rizzo, C., Fasano, S., Grasso, G., La Barbera, L., Ciccia, F., & Guggino, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637829 · Cited by 360
Navarro-Compán, V., Sepriano, A., El-Zorkany, B., & van der Heijde, D. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221035 · Cited by 340
Self-citation
Metadata
- Authors
- Deodhar, A., van der Heijde, D., Gensler, L. S., Kim, T.-H., Maksymowych, W. P., Østergaard, M., Poddubnyy, D., Marzo-Ortega, H., Bessette, L., Tomita, T., Leung, A., Hojnik, M., Gallo, G., Li, X., Adams, D., Carlier, H., Sieper, J., Morin, F., Rahman, P., Ariel, F., Berman, A., Carrio, J., Lucero, E., Cocco, J. M., Hidalgo, R. P., Velasco, J., Viola, D. O., Grisar, J., Resch, H., Scheinecker, C., Melazzi, A. C., Roimicher, L., Scotton, A. S., Rodriguez, A. A. B., Molina, F. F. C., Barragan, S. D., Skinner, C. M., Tena, C. F. P., Remus, C. R. R., Rodriguez, J. C. R., Hong, S.-J., Kang, S. W., Lee, C. K., Lee, E. B., Lee, S. H., Park, M.-C., Lee, S.-H., Dokoupilova, E., Dvorak, Z., Malcova, M., Pvelka, K., Eklund, K. K., Jarvinen, P., Karjalainen, A., Paimela, L., Taniguchi, Y., Tsuda, T., Tada, K., Dobashi, H., Inui, K., Ueki, Y., Matsumoto, Y., Hatta, K., Atsumi, T., Goto, H., Honjo, S., Matsui, K., Takakubo, Y., Neeck, G., Wagner, S., Braun, J., Blicharshi, T., Dudek, A., Hrycai, P., Plebanski, R., Drabiszcak-Piatkowska, J., Brzezicki, J., Krogulec, M., Opris-Belinski, D., Ramazan, A. M., Tronaru, L., van de Sande, M. G., Matsievskaya, G., Schmidt, E., Stanislav, M., Yakushin, S., Ershova, O., Rebroy, A., Churchill, M. A., Flint, K. P., Greenwald, M., Howell, M. P., Kaine, J. L., Kivitz, A., Klein, S. J., Mueller, E. C., Peters, E. A., Querubin, R., Sayers, M. E., Scoville, C. D., Shanahan, J. C., Roseff, R., Hull, J. E., Mallepalli, J. R., Sebai, M. B., Kimmel, S. C., Goddard, D. H., Mease, P. J., Harris, M. D., Mabaquiao, A. R., Diegel, R. J., Thai, C., Rivera, T. L., Perez-De Jesus, A., Soto-Raices, O., Toro-Torres, R., & Pantojas, C.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 395
- Issue
- 10217
- Pages
- 53-64
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2993436820
- Cited by
- 218
- References
- 1
- FWCI
- 19.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)32971-x
- The paper
- Deodhar, A., van der Heijde, D., Gensler, L. S., Kim, T.-H., Maksymowych, W. P., Østergaard, M., Poddubnyy, D., Marzo-Ortega, H., Bessette, L., Tomita, T., Leung, A., Hojnik, M., Gallo, G., Li, X., Adams, D., Carlier, H., Sieper, J., Morin, F., Rahman, P., . . . Pantojas, C. (2020). Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)32971-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.